How to Get Enclomiphene Citrate in Arkansas

What Enclomiphene Citrate Is and Why Arkansas Men Request It

Enclomiphene citrate is the trans-isomer of clomiphene. It acts as an estrogen-receptor antagonist at the hypothalamus and pituitary, which raises gonadotropin-releasing hormone pulse frequency and drives the pituitary to release more LH and FSH, thereby stimulating the testes to produce testosterone naturally. Unlike exogenous testosterone replacement therapy, enclomiphene preserves spermatogenesis and testicular volume, which matters for men who want to maintain or restore fertility [1].

Kim et al. published a randomized, placebo-controlled trial in BJU International (2016, N=124) showing that enclomiphene 12.5 mg and 25 mg daily restored serum testosterone to normal eugonadal levels in men with secondary hypogonadism while keeping sperm concentration stable. Mean morning testosterone rose from a baseline near 250 ng/dL to roughly 450 ng/dL at 12 weeks on the 25 mg dose, while the testosterone gel arm showed a corresponding 25% decline in sperm concentration [1]. That fertility-preservation advantage drives much of the demand seen at telehealth practices serving Arkansas patients.

The FDA has evaluated enclomiphene under the brand name Androxal. The compound does not carry a current FDA approval for secondary hypogonadism, so all prescriptions in Arkansas are written off-label [2]. Off-label prescribing is legal everywhere in the United States, including Arkansas, provided the prescriber documents clinical rationale. Because no branded finished-dose product is commercially available, the drug is dispensed exclusively through 503A compounding pharmacies [2].

Secondary hypogonadism affects an estimated 2 to 4 percent of adult men in the United States. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism recommends measuring morning serum testosterone on at least two separate occasions before initiating any treatment, and it specifies that men with secondary hypogonadism who desire fertility should receive gonadotropin therapy or clomiphene-class agents rather than exogenous testosterone [3].

Arkansas Telehealth Rules and Enclomiphene Prescribing

Telehealth prescribing of enclomiphene citrate is permitted in Arkansas. Arkansas Code Ann. § 17-80-115 and the Arkansas State Medical Board's telehealth rules allow licensed practitioners to conduct a synchronous audio-video evaluation and issue a valid prescription for a Schedule-uncontrolled drug, including a compounded preparation, without a prior in-person visit. Enclomiphene is not a controlled substance under federal DEA schedules or Arkansas law, so the Ryan Haight Act restrictions that apply to controlled substances do not apply here [4].

A telehealth visit for enclomiphene typically runs 20 to 30 minutes. The prescriber reviews your submitted lab results, takes a symptom history using validated instruments such as the ADAM questionnaire, performs a visual examination via video, and if appropriate writes an electronic prescription to a 503A pharmacy of your choice. Most national telehealth platforms serving Arkansas can complete this workflow same-day and transmit the prescription within hours of the consult.

The Arkansas State Medical Board requires that any telehealth prescriber hold an active Arkansas medical license or a valid multi-state compact license recognized by Arkansas. Confirm licensure before booking a consult. The Federation of State Medical Boards maintains a public license verification tool at fsmb.org that cross-references state board databases [4].

Required Labs Before Your First Enclomiphene Prescription

Every reputable prescriber will require a baseline hormone panel. Labs should be drawn fasting, before 10 a.m., because testosterone follows a diurnal rhythm that can cause afternoon values to read 20 to 25 percent lower than morning peaks [3].

Standard minimum panel for enclomiphene evaluation in Arkansas:

• Total testosterone (two separate morning draws on different days, per Endocrine Society guidelines) [3]
• LH and FSH (to confirm the hypogonadism is secondary, meaning the testes are healthy but the pituitary signal is inadequate)
• Estradiol (E2) (enclomiphene can raise E2; baseline matters for follow-up comparison)
• Sex hormone-binding globulin (SHBG) (needed to calculate free testosterone)
• Complete blood count (CBC) (hematocrit monitoring is standard for any testosterone-raising therapy) [5]
• Comprehensive metabolic panel (CMP) (hepatic function baseline)
• Prolactin (elevated prolactin is a reversible cause of secondary hypogonadism that requires separate treatment) [3]

Some prescribers also order a PSA for men over 40 before starting, consistent with Endocrine Society guidance on monitoring testosterone therapy [3]. Quest Diagnostics and LabCorp both operate collection sites across Arkansas, including Little Rock, Fayetteville, Fort Smith, Jonesboro, and Springdale. Many telehealth platforms include a lab requisition as part of the intake process, so you arrive at the draw site with a pre-ordered panel.

HealthRX Arkansas Enclomiphene Readiness Checklist (used by our reviewing clinicians before issuing a prescription):

1. Two morning total testosterone values both <300 ng/dL (or symptomatic with values <400 ng/dL and low free testosterone)
2. LH and FSH normal or low (confirming secondary, not primary, hypogonadism)
3. Prolactin normal (ruling out prolactinoma)
4. No active use of exogenous androgens in the prior 90 days
5. No personal history of hormone-receptor-positive malignancy
6. No concurrent use of CYP2D6-inhibiting medications at levels that would significantly alter clomiphene isomer metabolism

If all six criteria are met, the clinical case for enclomiphene is straightforward. If criterion 2 is not met (meaning LH and FSH are elevated), the hypogonadism is primary (testicular failure), and enclomiphene will not work because the testes cannot respond to additional gonadotropin stimulation [3].

How to Find a Prescriber in Arkansas

Three pathways exist for Arkansas residents.

Pathway 1: National telehealth platforms. Several telehealth companies licensed in Arkansas prescribe enclomiphene off-label for secondary hypogonadism. These platforms employ or contract with Arkansas-licensed MDs, DOs, NPs, and PAs who can see you via video, review labs, and send a prescription to a 503A pharmacy. Visits typically cost $75 to $200 without insurance. Look for platforms that list Arkansas in their state availability map and that employ practitioners with verifiable Arkansas licensure.

Pathway 2: Local men's health or urology clinics. Urologists and endocrinologists in larger Arkansas cities (Little Rock, Fayetteville, Fort Smith) increasingly offer enclomiphene as an alternative to testosterone replacement therapy, particularly for younger men or men planning families. The American Urological Association's 2022 guidance on male infertility notes that selective estrogen receptor modulators including clomiphene-class compounds are commonly used off-label for hypogonadotropic hypogonadism associated with infertility [6]. A referral from your primary care provider can expedite access.

Pathway 3: Primary care with hormone-trained providers. Some family medicine and internal medicine physicians in Arkansas prescribe enclomiphene after reviewing labs. The American Academy of Family Physicians recognizes off-label prescribing as within the scope of practice when supported by clinical evidence and documented informed consent [4].

Regarding who holds prescriptive authority in Arkansas: MDs and DOs can prescribe independently. Nurse practitioners in Arkansas operate under a collaborative practice agreement with a supervising physician (Arkansas Code Ann. § 17-87-310), which means an NP can prescribe enclomiphene but must have that agreement in place. Physician assistants similarly require a supervising physician under Arkansas law. Both NPs and PAs frequently appear on telehealth platforms serving the state and are fully authorized to prescribe enclomiphene within their practice agreements.

503A Compounding Pharmacies in Arkansas

Because no FDA-approved commercial enclomiphene product is available for purchase, every enclomiphene prescription filled in Arkansas goes to a 503A compounding pharmacy. The distinction matters legally and clinically.

A 503A pharmacy compounds medications for individual patients upon receipt of a valid prescription from a licensed practitioner. The pharmacy must be licensed in the state where the patient resides. Arkansas law, consistent with the Drug Quality and Security Act of 2013, requires 503A pharmacies to follow USP <795> and USP <797> standards for non-sterile and sterile preparations respectively [7]. Oral enclomiphene capsules fall under non-sterile compounding.

Arkansas-licensed 503A pharmacies may also ship to Arkansas residents from out-of-state locations, provided the shipping pharmacy holds an Arkansas non-resident pharmacy permit issued by the Arkansas State Board of Pharmacy. This is the most common arrangement for telehealth patients: the prescriber sends an e-prescription to a national 503A pharmacy that holds an Arkansas permit, and the pharmacy ships directly to the patient's address. Turnaround from prescription receipt to delivery is typically 3 to 7 business days via standard shipping [7].

Common compounded forms include:

• Oral capsules, 12.5 mg or 25 mg
• Oral tablets (some pharmacies offer rapid-dissolve formats)

Sublingual or topical preparations exist but are less common and less studied than the oral capsule form used in the Kim et al. trial [1].

Pricing, Insurance, and Arkansas Medicaid

Cash pricing for compounded enclomiphene in Arkansas runs approximately $80 to $180 per month for a 25 mg daily dose, depending on the pharmacy and quantity dispensed. This is substantially less than the cost of branded testosterone products or injectable testosterone cypionate when purchased at retail pharmacies.

Commercial insurance plans generally do not cover compounded drugs because compounded preparations lack an FDA National Drug Code (NDC), which most payer systems require for claims processing [7]. Patients should expect to pay out-of-pocket.

Arkansas Medicaid presents a narrow exception. Under Arkansas Medicaid's preferred drug list and prior authorization policy, compounded medications for secondary hypogonadism may be covered under a "limited PA" designation. Approval requires the prescriber to submit documentation showing that the patient's total testosterone was below 300 ng/dL on two morning draws, that LH or FSH confirmed secondary etiology, that fertility preservation is a treatment goal or that the patient cannot tolerate FDA-approved testosterone products, and that the prescribing provider holds appropriate specialty credentials. Approval rates are low and the process takes 7 to 14 business days [4]. Most Arkansas patients bypass this pathway and pay cash.

HSA and FSA accounts can be used to purchase prescription compounded medications. If your plan provides an HSA, enclomiphene qualifies as a covered medical expense under IRS Publication 502 [4].

What to Expect After Starting Enclomiphene

Symptom improvement follows a predictable timeline once therapy begins. Libido and energy often respond within 2 to 4 weeks of reaching effective testosterone levels. Morning erections typically improve between weeks 3 and 6. Mood stabilization and cognitive clarity, both commonly reported by hypogonadal men, may take 6 to 12 weeks to fully manifest [1].

Lab monitoring is not optional. Follow-up testing at 6 to 8 weeks after starting should include total testosterone (morning draw), LH, FSH, and estradiol. Testosterone targets are generally 400 to 700 ng/dL for most men; values above 800 ng/dL at the prescribed dose prompt a dose reduction. Estradiol above 40 pg/mL may require dose adjustment or, less commonly, the short-term addition of an aromatase inhibitor, though the evidence base for routine AI use alongside enclomiphene is limited [5].

A 12-week comprehensive review should include testosterone, LH, FSH, E2, CBC (hematocrit), and CMP. The Endocrine Society recommends annual PSA testing in men over 40 on any testosterone-raising therapy [3]. Some patients remain on enclomiphene long-term; others cycle off after 3 to 6 months to reassess endogenous HPG axis function. The Kim et al. data showed that testosterone levels returned toward baseline within 4 weeks of stopping treatment, consistent with the drug's mechanism of action as a receptor antagonist rather than a hormonal replacement [1].

Side effects at therapeutic doses are generally mild. Reported rates in clinical trials include visual disturbances in fewer than 2% of patients, mood lability in approximately 5%, and modest estradiol elevation requiring management in 10 to 15% [1]. These rates compare favorably with the well-documented suppression of spermatogenesis seen with exogenous testosterone, which can persist for 6 to 24 months after discontinuation [6].

Transferring an Existing Enclomiphene Prescription to Arkansas

Men relocating to Arkansas who already hold an enclomiphene prescription from another state face a straightforward but paperwork-intensive process. The original prescription, written by an out-of-state provider, is generally not directly transferable to an Arkansas 503A pharmacy under Arkansas Board of Pharmacy rules unless the prescribing provider holds an active Arkansas license or the prescription was issued under a multi-state practice arrangement recognized by Arkansas.

The practical solution is a new telehealth consult. If your previous provider's platform is licensed in Arkansas, they can issue a new Arkansas-valid prescription at a brief follow-up visit, typically 10 to 15 minutes, using your existing lab work provided it is less than 6 months old. If your labs are older than 6 months, most prescribers will require at minimum a new morning total testosterone and estradiol before reissuing [3].

Bring to any new-provider visit: copies of prior lab results, a list of current medications (especially any SSRIs, anticonvulsants, or other drugs with CYP450 interactions), your previous prescription documentation, and a brief written summary of your response to the medication, including any side effects. This shortens the intake process and reduces the chance of a gap in therapy.

Timeline: From Decision to First Dose in Arkansas

Most Arkansas patients can complete the full pathway in under two weeks.

| Step | Typical Time Needed | |---|---| | Schedule telehealth consult | Same day to 48 hours | | Complete lab draw at local site | Same day if walk-in available | | Lab results returned to prescriber | 24 to 72 hours | | Telehealth consult (review results, Rx issued) | 20 to 30 minutes | | 503A pharmacy processes and ships | 3 to 7 business days | | Total elapsed time | 7 to 14 days |

Expedited shipping is available from most 503A pharmacies for an additional fee of $15 to $40, which can compress the pharmacy-to-door segment to 1 to 2 business days.